drugset / Trial / NCT00218231

Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia

NCT00218231

Phase 2 Completed 48 enrolled National Institute on Drug Abuse (NIDA)
RandomizedCrossoverDouble-blindTreatment

Summary

Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.

Timeline

Start
2004-01
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 300 mg